8th NovAliX Conference

COVID-19 UPDATE

With the NovAliX Conference due to take place in June, our team at LDO continues to plan confidently for it. We currently have NO plans to postpone or cancel.

We remain attentive to the development of the situation and follow the recommendations of the relevant health authorities. As this unprecedented situation is changing every day, we remain watchful but also focused on delivering what is an important event for the Community.

We will post updates on the website and inform all registered participants if the situation changes.

In case the symposium has to be postponed, registrations will automatically be valid for the news dates. In case of cancellation due to force majeure, delegates will be offered a voucher to access the same or a similar event scheduled at an alternative date.

Committees

Conference Chairman

Dr Jean-Paul RENAUD (Urania Therapeutics, Illkirch, France)

Scientific Committee

Prof. Michelle ARKIN (University of California, San Francisco, United States)
Dr Jim BRYSON (Bristol-Myers-Squibb, Princeton, United States)
Dr Dirksen BUSSIERE (Novartis, Emeryville, United States)
Dr Claudio CIFERRI (Genentech, South San Francisco, United States)
Dr MariJean EGGEN (Eli Lilly, Indianapolis, United States)
Dr Dan ERLANSON (Frontier Medicines, South San Francisco, United States)
Dr Jean-Paul RENAUD (Urania Therapeutics, Illkirch, France)
Dr Chaohong SUN (Abbvie, North Chicago, United States)
Dr Daniel WYSS (Merck, Kenilworth, United States)
Dr Denis ZEYER (NovAliX, Illkirch, France)

Copyright 2020 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys